RxDoctor Payments Data

Daniel Jones

Molecular Genetic Pathology · Columbus, OHNPI 1205884459

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,600 of the $1,600 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Eli Lilly.

$1,600in general payments, 2019–2025

Across 1 payment — averaging $1600.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2K
$351,395in research payments, 2019–2025

Across 8 payments — averaging $43,924 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acerta Pharma LLC$168K
  • Pharmacyclics LLC, An Abbvie Company$103K
  • AstraZeneca$76K
  • Aptevo Therapeutics Inc$4K
  • Novartis$608

What the payments were for

  • Consulting fees$1,600100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly1$1,600

How this compares

Too few molecular genetic pathology providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$66,460
Medicare patients
604
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other molecular genetic pathology in Columbus

Where these figures come from

Is this you, or does something look wrong? →